Intravitreal bevacizumab (Avastin) treatment is safe in terms of intraocular and blood pressure
- 11 October 2006
- journal article
- Published by Wiley in Acta Ophthalmologica Scandinavica
- Vol. 85 (1) , 119-120
Abstract
No abstract availableKeywords
This publication has 4 references indexed in Scilit:
- Optical Coherence Tomography Findings After an Intravitreal Injection of Bevacizumab (Avastin®) for Neovascular Age-Related Macular DegenerationOphthalmic Surgery, Lasers and Imaging Retina, 2005
- Systemic Bevacizumab (Avastin) Therapy for Neovascular Age-Related Macular DegenerationTwelve-Week Results of an Uncontrolled Open-Label Clinical StudyOphthalmology, 2005
- Intraocular pressure after intravitreal injection of triamcinolone acetonideBritish Journal of Ophthalmology, 2003
- Preoperative infection prophylaxis with 1 % polyvidon-iodine solution based on the example of conjunctival staphylococciDer Ophthalmologe, 1999